Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

Normoglycemic individuals spent 87% of their daily time in in the “tight range” of glucose levels (70-140 mg/dL) and the remainder above 140 mg/dL.

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...

Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

Breakthrough stem cell transplants for diabetes have allowed patients to produce their own insulin, offering hope for a ...

A 10-year-old boy from New Town has been living life to the fullest despite his recent diagnosis of Type 1 diabetes.

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

To meet international guidelines, New Zealand needs to double the workforce that supports people with diabetes. Unless that ...

Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...